{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:28:02Z","timestamp":1780468082151,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ucl.2021.12.002","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T20:51:22Z","timestamp":1649796682000},"page":"209-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacotherapy for Erectile Dysfunction in 2021 and Beyond"],"prefix":"10.1016","volume":"49","author":[{"given":"Farnoosh","family":"Nik-Ahd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan W.","family":"Shindel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ucl.2021.12.002_bib1","first-page":"633","article-title":"Erectile Dysfunction: AUA Guideline","volume":"200","author":"Burnett","year":"2018","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.002_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/0970-1591.94946","article-title":"The history of ginseng in the management of erectile dysfunction in ancient China (3500-2600 BCE)","volume":"28","author":"Nair","year":"2012","journal-title":"Indian J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.002_bib3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40265-018-0897-3","article-title":"Herbal Dietary Supplements for Erectile Dysfunction: A Systematic Review and Meta-Analysis","volume":"78","author":"Borrelli","year":"2018","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.ucl.2021.12.002_bib4","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1464-410X.2005.05797.x","article-title":"How (not) to communicate new scientific information: a memoir of the famous Brindley lecture","volume":"96","author":"Klotz","year":"2005","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.002_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJM199201093260203","article-title":"Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission","volume":"326","author":"Rajfer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.ucl.2021.12.002_bib6","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJM199805143382001","article-title":"Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group","volume":"338","author":"Goldstein","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.002_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ucl.2005.08.007","article-title":"Physiology of penile erection and pathophysiology of erectile dysfunction","volume":"32","author":"Dean","year":"2005","journal-title":"Urol Clin North Am"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.002_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ucl.2021.06.009","article-title":"Physiology of Erection and Pathophysiology of Erectile Dysfunction","volume":"48","author":"MacDonald","year":"2021","journal-title":"Urol Clin North Am"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.002_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/14656566.2015.1011124","article-title":"Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients?","volume":"16","author":"Aversa","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 3","key":"10.1016\/j.ucl.2021.12.002_bib10","first-page":"S17","article-title":"Pharmacologic treatment of erectile dysfunction","volume":"4","author":"Steers","year":"2002","journal-title":"Rev Urol"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.002_bib11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ijir.2008.10","article-title":"Discovery of NO in the penis","volume":"20","author":"Rajfer","year":"2008","journal-title":"Int J Impot Res"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.002_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-1119(98)00303-5","article-title":"Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase","volume":"216","author":"Loughney","year":"1998","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.002_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1432-1327.1998.2550391.x","article-title":"Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene","volume":"255","author":"Yanaka","year":"1998","journal-title":"Eur J Biochem"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.002_bib14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.tips.2011.02.019","article-title":"Phosphodiesterases and cardiac cGMP: evolving roles and controversies","volume":"32","author":"Zhang","year":"2011","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.002_bib15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents","volume":"109","author":"Lugnier","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.002_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.002_bib17","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1124\/mol.106.028688","article-title":"A\u00a046-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization","volume":"70","author":"Blount","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ucl.2021.12.002_bib18","doi-asserted-by":"crossref","first-page":"111128","DOI":"10.1016\/j.biopha.2020.111128","article-title":"Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors","volume":"134","author":"Ahmed","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.002_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.sxmr.2017.08.001","article-title":"Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction","volume":"6","author":"Yafi","year":"2018","journal-title":"Sex Med Rev"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.002_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/CIRCULATIONAHA.110.944603","article-title":"Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension","volume":"122","author":"Schwartz","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.002_bib21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.euf.2019.05.007","article-title":"Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis","volume":"6","author":"Kallidonis","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ucl.2021.12.002_bib22","author":"Charles Welliver"},{"issue":"8","key":"10.1016\/j.ucl.2021.12.002_bib23","first-page":"1579","article-title":"Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?","volume":"17","author":"Rezaee","year":"2020","journal-title":"J\u00a0Sex Med"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.002_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0002-9394(14)70999-7","article-title":"Incidence of nonarteritic anterior ischemic optic neuropathy","volume":"123","author":"Hattenhauer","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ucl.2021.12.002_bib25","series-title":"Viagra (sildenafil citrate) : the remarkable story of the discovery and launch","author":"Katzenstein","year":"2001"},{"issue":"11","key":"10.1016\/j.ucl.2021.12.002_bib26","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00018-005-4533-5","article-title":"Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development","volume":"62","author":"Jeon","year":"2005","journal-title":"Cell Mol Life Sci CMLS"},{"issue":"17","key":"10.1016\/j.ucl.2021.12.002_bib27","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.CIR.0000099502.17776.C2","article-title":"Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension","volume":"108","author":"Michelakis","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.002_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.ijir.3901522","article-title":"The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy","volume":"19","author":"Mehrotra","year":"2007","journal-title":"Int J Impot Res"},{"issue":"9","key":"10.1016\/j.ucl.2021.12.002_bib30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/BF03349261","article-title":"The use of phosphodiesterase 5 inhibitors with concomitant medications","volume":"31","author":"Corona","year":"2008","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.002_bib31","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2165\/00003495-199957060-00015","article-title":"Sildenafil: a review of its use in erectile dysfunction","volume":"57","author":"Langtry","year":"1999","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.002_bib32","first-page":"1228","article-title":"Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study","volume":"180","author":"Roehrborn","year":"2008","journal-title":"J\u00a0Urol"},{"issue":"10","key":"10.1016\/j.ucl.2021.12.002_bib33","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1517\/13543776.2011.614435","article-title":"Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010)","volume":"21","author":"Bell","year":"2011","journal-title":"Expert Opin Ther Pat"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.002_bib35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/BF02014937","article-title":"Cardiopulmonary effects and safety of prostaglandin E1: A review","volume":"3","author":"Heidrich","year":"1994","journal-title":"Int J Angiology"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.002_bib36","first-page":"1760","article-title":"Atropine role in the pharmacological erection test: study of 228 patients","volume":"158","author":"Sogari","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2021.12.002_bib37","series-title":"Key clinical trials in erectile dysfunction","first-page":"20","article-title":"Defining the Therapeutic Ratio for Intracavernosal Administration of Prostaglandin E1 (Alprostadil)","year":"2007"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.002_bib38","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0090-4295(96)00435-9","article-title":"Influence of the method of intracavernous injection on penile rigidity: a possible pharmacokinetic explanation","volume":"49","author":"de Meyer","year":"1997","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.002_bib39","first-page":"1227","article-title":"Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum","volume":"151","author":"van Ahlen","year":"1994","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.002_bib40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00003495-199550030-00005","article-title":"Pharmacological management of erectile dysfunction","volume":"50","author":"Montorsi","year":"1995","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.002_bib41","first-page":"961","article-title":"Peyronie's-like plaque after penile injection of prostaglandin E1","volume":"152","author":"Chen","year":"1994","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2021.12.002_bib42","series-title":"Acute Ischemic priapism: an AUA\/SMSNA Guideline","author":"Bivalacqua","year":"2021"},{"key":"10.1016\/j.ucl.2021.12.002_bib43","author":"Corporation"},{"issue":"259","key":"10.1016\/j.ucl.2021.12.002_bib44","first-page":"A1013","article-title":"The pharmacokinetics of transurethral alprostadil (Prostaglandin E1) in men with erectile dysfunction","volume":"157","author":"Gesundheit","year":"1997","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.002_bib45","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1464-410X.2005.05413.x","article-title":"Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and\/or vardenafil monotherapy after radical retropubic prostatectomy","volume":"95","author":"Mydlo","year":"2005","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.002_bib46","first-page":"1992","article-title":"Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy","volume":"162","author":"McMahon","year":"1999","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.002_bib47","first-page":"262","article-title":"Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction","volume":"28","author":"Lasker","year":"2013","journal-title":"Physiology (Bethesda)"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.002_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrurol.2017.181","article-title":"Stimulators and activators of soluble guanylate cyclase for urogenital disorders","volume":"15","author":"M\u00f3nica","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.002_bib49","first-page":"1155","article-title":"Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury","volume":"189","author":"Hannan","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.002_bib50","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/bju.13691","article-title":"Additive effects of the Rho kinase inhibitor Y-27632 and vardenafil on relaxation of the corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure","volume":"119","author":"Uvin","year":"2017","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.002_bib51","first-page":"423","article-title":"Evaluation and Management of Testosterone Deficiency: AUA Guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.002_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852914000832","article-title":"Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder","volume":"20","author":"Stahl","year":"2015","journal-title":"CNS Spectr"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.002_bib53","first-page":"15","article-title":"Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder","volume":"8","author":"Stahl","year":"2011","journal-title":"J\u00a0Sex Med"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.002_bib54","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.urology.2004.10.060","article-title":"Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response","volume":"65","author":"Diamond","year":"2005","journal-title":"Urology"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014321019108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014321019108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:54:57Z","timestamp":1758808497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014321019108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0094014321019108"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2021.12.002","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy for Erectile Dysfunction in 2021 and Beyond","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2021.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}